Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 44 min ago
Peer-reviewedCC BY-NC-NDNpj biomedical innovations

Challenges and innovations in cardiac AAV gene delivery as a platform for cardiac regeneration.

  • Gabriella Kabboul1
  • Alejandro Izurieta Muñoz2
  • Muath Bishawi3
  • Christopher B Doering4
  • Rebecca D Levit5
5 affiliations
  1. 1Division of Engineering in Medicine,Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  2. 2Department of Medicine, Division of Cardiology, Emory University, Atlanta, GA, USA.
  3. 3Department of Surgery, Emory University, Atlanta, GA, USA.
  4. 4Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, USA.
  5. 5Division of Engineering in Medicine,Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. [email protected].
Read full textPDFDOICite

Abstract

Gene therapies are at the forefront of potential treatments for cardiovascular diseases, but clinical translation remains limited by poor myocardial access and retention, systemic distribution, and immune-mediated toxicities. Heavily underexplored, the route of administration dictates efficacy and safety, ultimately influencing therapeutic outcomes. This review addresses the role of delivery in overcoming these challenges in cardiac adeno-associated viral therapies. Emphasis is placed on biomaterial-based delivery approaches to improve therapeutic outcomes.

Related

  1. One Health in action: regional innovations and shared challenges in addressing antimicrobial resistance
    Godwin Pius Ohemu, Adam Dale, Babafela Awosile +23
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textMicrobiologyCrossref
  2. Platelet-engineered AAV silencing of myocardial CD36 reprograms fatty acid metabolism to promote cardiac regeneration in male mice
    Ning Zhang, Mei Hua Ting, Siyuan Liu +10
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textGenetics & genomicsCrossref
  3. 857 Development of an mRNA cancer vaccine platform enabling flexible antigen exchange and dendritic cell selected delivery to overcome immune tolerance
    So-Young Kim, Helen Cho, Sojin Lee
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textImmunologyDOAJ
  4. Biomaterial-based local delivery of anti-inflammatory drugs, cytokines, and growth factors for bone regeneration
    Jiaming Shi, Jiaming Shi, Jiahe Liu +6
    Frontiers in Bioengineering and BiotechnologyPeer-reviewedCC BYFull textSystems & synthetic biologyDOAJEurope PMC
  5. Bispecific VSV-G Engagers: A Platform for Cell-Type-Specific Delivery of Viral Vectors
    G. N. Nenavath, D. Gataulin, M. Eisenstein +15
    bioRxivPreprintAll rights reservedFull textCell biologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{kabboul2026challenges,
  title = {{Challenges and innovations in cardiac AAV gene delivery as a platform for cardiac regeneration.}},
  author = {Gabriella Kabboul and Alejandro Izurieta Muñoz and Muath Bishawi and Christopher B Doering and Rebecca D Levit},
  journal = {Npj biomedical innovations},
  year = {2026},
  month = nov,
  doi = {10.1038/s44385-026-00117-2},
  url = {https://europepmc.org/article/MED/42972024},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Challenges and innovations in cardiac AAV gene delivery as a platform for cardiac regeneration.
AU  - Gabriella Kabboul
AU  - Alejandro Izurieta Muñoz
AU  - Muath Bishawi
AU  - Christopher B Doering
AU  - Rebecca D Levit
PY  - 2026
DA  - 2026/11/02
JO  - Npj biomedical innovations
DO  - 10.1038/s44385-026-00117-2
UR  - https://europepmc.org/article/MED/42972024
AB  - Gene therapies are at the forefront of potential treatments for cardiovascular diseases, but clinical translation remains limited by poor myocardial access and retention, systemic distribution, and immune-mediated toxicities. Heavily underexplored, the route of administration dictates efficacy and safety, ultimately influencing therapeutic outcomes. This review addresses the role of delivery in overcoming these challenges in cardiac adeno-associated viral therapies. Emphasis is placed on biomaterial-based delivery approaches to improve therapeutic outcomes.
SN  - 3005-1444
ER  -